AAM Welcomes Biosimilar Access Bill
US Legislation Would Boost Prescribing And Demonstrate Savings
A US bill aimed at promoting biosimilars by encouraging greater prescribing rates and creating a shared savings demonstration program for biosimilars has been warmly welcomed by the AAM.
You may also be interested in...
A wave of recent biosimilar launches in the US has provided multi-source competition on several major brands and stands to boost the country’s biosimilars market, according to Sean McGowan, senior director of biosimilars at AmerisourceBergen.
The FDA’s acceptance of Amneal’s filing for bevacizumab brings the company a step closer to its goal of launching a US biosimilar every year to 2023.
As part of a “structured dialog” initiated with pharmaceutical industry stakeholders by the European Commission, local off-patent industry association Medicines for Europe has set out the key reforms needed to bolster the sector.